190 related articles for article (PubMed ID: 29170116)
1. In vivo controlled release of fenretinide from long-acting release depots for chemoprevention of oral squamous cell carcinoma recurrence.
Nieto K; Pei P; Wang D; Mallery SR; Schwendeman SP
Int J Pharm; 2018 Mar; 538(1-2):48-56. PubMed ID: 29170116
[TBL] [Abstract][Full Text] [Related]
2. Microencapsulation of amorphous solid dispersions of fenretinide enhances drug solubility and release from PLGA in vitro and in vivo.
Nieto K; Mallery SR; Schwendeman SP
Int J Pharm; 2020 Aug; 586():119475. PubMed ID: 32525080
[TBL] [Abstract][Full Text] [Related]
3. Development of PLGA-based injectable delivery systems for hydrophobic fenretinide.
Wischke C; Zhang Y; Mittal S; Schwendeman SP
Pharm Res; 2010 Oct; 27(10):2063-74. PubMed ID: 20668921
[TBL] [Abstract][Full Text] [Related]
4. Design of Controlled Release PLGA Microspheres for Hydrophobic Fenretinide.
Zhang Y; Wischke C; Mittal S; Mitra A; Schwendeman SP
Mol Pharm; 2016 Aug; 13(8):2622-30. PubMed ID: 27144450
[TBL] [Abstract][Full Text] [Related]
5. Effect of formulation parameters on 2-methoxyestradiol release from injectable cylindrical poly(DL-lactide-co-glycolide) implants.
Desai KG; Mallery SR; Schwendeman SP
Eur J Pharm Biopharm; 2008 Sep; 70(1):187-98. PubMed ID: 18472254
[TBL] [Abstract][Full Text] [Related]
6. Development and in vitro-in vivo evaluation of fenretinide-loaded oral mucoadhesive patches for site-specific chemoprevention of oral cancer.
Desai KG; Mallery SR; Holpuch AS; Schwendeman SP
Pharm Res; 2011 Oct; 28(10):2599-609. PubMed ID: 21674264
[TBL] [Abstract][Full Text] [Related]
7. Formulation and evaluation of biodegradable nanoparticles for the oral delivery of fenretinide.
Graves RA; Ledet GA; Glotser EY; Mitchner DM; Bostanian LA; Mandal TK
Eur J Pharm Sci; 2015 Aug; 76():1-9. PubMed ID: 25933716
[TBL] [Abstract][Full Text] [Related]
8. Formulation and in vitro-in vivo evaluation of black raspberry extract-loaded PLGA/PLA injectable millicylindrical implants for sustained delivery of chemopreventive anthocyanins.
Desai KG; Olsen KF; Mallery SR; Stoner GD; Schwendeman SP
Pharm Res; 2010 Apr; 27(4):628-43. PubMed ID: 20148292
[TBL] [Abstract][Full Text] [Related]
9. Benefits of Multifaceted Chemopreventives in the Suppression of the Oral Squamous Cell Carcinoma (OSCC) Tumorigenic Phenotype.
Mallery SR; Wang D; Santiago B; Pei P; Schwendeman SP; Nieto K; Spinney R; Tong M; Koutras G; Han B; Holpuch A; Lang J
Cancer Prev Res (Phila); 2017 Jan; 10(1):76-88. PubMed ID: 27756753
[TBL] [Abstract][Full Text] [Related]
10. Formulation and characterization of injectable poly(DL-lactide-co-glycolide) implants loaded with N-acetylcysteine, a MMP inhibitor.
Desai KG; Mallery SR; Schwendeman SP
Pharm Res; 2008 Mar; 25(3):586-97. PubMed ID: 17891553
[TBL] [Abstract][Full Text] [Related]
11. Improving release completeness from PLGA-based implants for the acid-labile model protein ovalbumin.
Duque L; Körber M; Bodmeier R
Int J Pharm; 2018 Mar; 538(1-2):139-146. PubMed ID: 29355654
[TBL] [Abstract][Full Text] [Related]
12. In vitro and in vivo release of ciprofloxacin from PLGA 50:50 implants.
Ramchandani M; Robinson D
J Control Release; 1998 Jul; 54(2):167-75. PubMed ID: 9724903
[TBL] [Abstract][Full Text] [Related]
13. Antitumor activity of 4-(N-hydroxyphenyl)retinamide conjugated with poly(L-glutamic acid) against ovarian cancer xenografts.
Zou C; Brewer M; Cao X; Zang R; Lin J; Deng Y; Li C
Gynecol Oncol; 2007 Dec; 107(3):441-9. PubMed ID: 17854871
[TBL] [Abstract][Full Text] [Related]
14. PLGA nanoparticles for the oral delivery of 5-Fluorouracil using high pressure homogenization-emulsification as the preparation method and in vitro/in vivo studies.
Li X; Xu Y; Chen G; Wei P; Ping Q
Drug Dev Ind Pharm; 2008 Jan; 34(1):107-15. PubMed ID: 18214762
[TBL] [Abstract][Full Text] [Related]
15. Antitumor Efficacy and Toxicity of 5-Fluorouracil-Loaded Poly(Lactide Co-glycolide) Pellets.
Leelakanok N; Geary SM; Salem AK
J Pharm Sci; 2018 Feb; 107(2):690-697. PubMed ID: 29031952
[TBL] [Abstract][Full Text] [Related]
16. Injectable Sustained-Release Depots of PLGA Microspheres for Insoluble Drugs Prepared by hot-Melt Extrusion.
Guo Y; Yang Y; He L; Sun R; Pu C; Xie B; He H; Zhang Y; Yin T; Wang Y; Tang X
Pharm Res; 2017 Oct; 34(10):2211-2222. PubMed ID: 28741064
[TBL] [Abstract][Full Text] [Related]
17. Goserelin Acetate Loaded Poloxamer Hydrogel in PLGA Microspheres: Core-Shell Di-Depot Intramuscular Sustained Release Delivery System.
Qi P; Bu R; Zhang H; Yin J; Chen J; Zhang A; Gou J; Yin T; Zhang Y; He H; Wang P; Tang X; Wang Y
Mol Pharm; 2019 Aug; 16(8):3502-3513. PubMed ID: 31251642
[TBL] [Abstract][Full Text] [Related]
18. Chemopreventive efficacy of curcumin-loaded PLGA microparticles in a transgenic mouse model of HER-2-positive breast cancer.
Grill AE; Shahani K; Koniar B; Panyam J
Drug Deliv Transl Res; 2018 Apr; 8(2):329-341. PubMed ID: 28417445
[TBL] [Abstract][Full Text] [Related]
19. In Vitro-In Vivo Relationship of Amorphous Insoluble API (Progesterone) in PLGA Microspheres.
Pu C; Wang Q; Zhang H; Gou J; Guo Y; Tan X; Xie B; Yin N; He H; Zhang Y; Wang Y; Yin T; Tang X
Pharm Res; 2017 Dec; 34(12):2787-2797. PubMed ID: 28948463
[TBL] [Abstract][Full Text] [Related]
20. Accelerated in vitro release testing method for a long-acting peptide-PLGA formulation.
Goel M; Leung D; Famili A; Chang D; Nayak P; Al-Sayah M
Eur J Pharm Biopharm; 2021 Aug; 165():185-192. PubMed ID: 33992753
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
